Deep Venous Disease Treatment Devices – Market Insights – Global

The uptake of innovative higher-priced devices, increasing PE treatment penetration, and favorable clinical data will drive strong growth in the global deep venous disease treatment device market over the forecast period; however, cost-constraints in some regions will hinder the pace of market expansion to some extent.

This Medtech 360 Report provides comprehensive data and analysis on the state of the global market for deep venous disease treatment devices from 2019 through 2033.

Market growth will be primarily driven by the powered thrombectomy device market, supported by rising procedure volumes and premium pricing.

How will the use of powered thrombectomy devices impact other treatment types, such as thrombectomy and thrombolysis, PTA-with-stenting, or IVCF placement?

To what extent has this affected the competitive landscape?

How will product improvements and improved patient management contribute to this growth?

What is the outlook for treatment trends for DVT and PE in the US, Europe, and Asia Pacific?

Will other treatments, such as CDT or embolectomy, follow similar trends?

Dedicated venous stents have been established as an effective tool for managing deep venous disease conditions.

How have PV stent recalls in 2021 affected the competitive landscape in this segment?

What factors are influencing the adoption of dedicated venous stents for challenging venous anatomies?

Are there any emerging competitors expected to enter the market in the coming years?

Competitive efforts conducted by key manufacturers focus on generating clinical evidence that supports their devices.

Are head-to-head clinical trials being conducted, and how will this affect the market?

How has the evidence generated for powered thrombectomy devices and PV stents impacted the competitive landscape?

Which ongoing clinical trials are most relevant, and to what extent will they impact future trends?

Access to premium-priced devices remains limited in some countries.

How does this affect the penetration of different treatment options in those countries?

What impact does the low penetration of premium-priced devices have on the competitive landscape in these regions?

Will competitive or regulatory pressures on ASPs make premium-priced devices more affordable?